Potent complement C3a receptor agonists derived from oxazole amino acids: Structure-activity relationships

Area of Science:

• Medicinal Chemistry
• Immunology
• Pharmacology

Background:

• The complement system plays a crucial role in innate and adaptive immunity.
• The C3a receptor (C3aR) is a key mediator of inflammatory responses.
• Endogenous C3a peptide is an agonist for C3aR, but its therapeutic use is limited.

Purpose of the Study:

• To develop novel, potent, and stable small-molecule agonists for the human C3a receptor (C3aR).
• To explore structure-activity relationships of modified peptide analogs.
• To identify compounds with therapeutic potential for C3aR-mediated conditions.

Main Methods:

• Peptide modification: Synthesized analogs of the C-terminal tripeptide of C3a (Leu-Ala-Arg).
• Chemical synthesis: Created a leucine-oxazole-arginine core structure via side-chain condensation.
• Functional assays: Evaluated calcium (Ca2+) release from human macrophages stimulated by synthesized compounds.

Main Results:

• Developed potent C3aR agonists from a near-inactive tripeptide precursor.
• Identified leucine-oxazole-arginine as a key structural motif.
• Achieved agonist potency comparable to endogenous C3a in stimulating Ca2+ release.
• Explored N-terminal modifications to optimize activity.

Conclusions:

• Novel small-molecule agonists for C3aR were successfully developed.
• The leucine-oxazole-arginine scaffold represents a promising basis for C3aR-targeting drugs.
• These findings offer new therapeutic avenues for inflammatory diseases by modulating C3aR signaling.